Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV Infection

Journal of Infectious Diseases

Volumn 196, Issue 10, 2007, Pages 1438-1446

  Villa, Luisa L ^a   Perez, Gonzalo ^b   Kjær, Susanne Krüger ^c   Paavonen, Jorma ^d   Lehtinen, Matti ^e   Muñoz, Nubia ^f   Sigurdsson, Kristján ^g   Hernandez Avila, Mauricio ^h   Iversen, Ole Eric ⁱ   Thoresen, Steinar ^j   García, Patricia J ^k   Majewski, Slawomir ^l   Eng, Hseon Tay ^m   Bosch, F Xavier ⁿ   Dillner, Joakim ^o   Olsson, Sven Eric ^p   Ault, Kevin A ^q   Brown, Darron R ^r   Ferris, Daron G ^s   Koutsky, Laura A ^t   Kurman, Robert J ^u   Myers, Evan R ^v   Barr, Eliav ^w   Boslego, John ^w   Bryan, Janine ^w   Esser, Mark T ^w   Hesley, Teresa M ^w   Nelson, Micki ^w   Railkar, Radha ^w   James, Margaret ^w   Sattler, Carlos ^w   Taddeo, Frank J ^w   Thornton, Annemarie R ^w   Vuocolo, Scott C ^w   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b National Research Center   (Colombia)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF TAMPERE   (Finland)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g ICELANDIC CANCER SOCIETY   (Iceland)

^h INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j CANCER REGISTRY OF NORWAY   (Norway)

^k UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^l MEDICAL UNIVERSITY OF WARSAW   (Poland)

^m KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

ⁿ BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^o LUND UNIVERSITY   (Sweden)

^p DANDERYD HOSPITAL   (Sweden)

^q EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^s MEDICAL COLLEGE OF GEORGIA   (United States)

^t UNIVERSITY OF WASHINGTON   (United States)

^u JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v DUKE UNIVERSITY MEDICAL CENTER   (United States)

^w MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE; VIRUS ANTIBODY; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; BRONCHOSPASM; CANCER SCREENING; CHILL; CLINICAL EVALUATION; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROENTERITIS; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HYPERTENSION; INJECTION SITE PAIN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VAGINA CANCER; VIRUS DETECTION; VULVA CANCER; WART VIRUS; BLOOD; CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 38049008823     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/522864     Document Type: Article

References (20)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65.
2. Gissmann L, zur Hausen H. Partial characterization of viral DNA from human genital warts (Condylomata acuminata). Int J Cancer 1980; 25:605-9.
3. Goodman A. Primary vaginal cancer. Surg Oncol Clin N Am 1998; 7:347-61.
4. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol 1997; 90:448-52.
5. Harper DM, Franco EL, Wheeler CM, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection of human papillomavirus type 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757-65.
6. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
7. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107:18-27.
8. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology 2005; 6:271-8.
9. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-27.
10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. FUTURE I Investigators. N Engl J Med 2007; 356:1928-43.
11. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781-9.
12. Froehlich H, Verma R. Arthus reaction to recombinant hepatitis B virus vaccine. Clin Infect Dis 2001; 33:906-8.
13. Ponvert C, Scheinmann P. Vaccine allergy and pseudo-allergy. Eur J Dermatol 2003; 13:10-5.
14. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114-9.
15. Opalka D, Lachman CE, MacMullen SA, et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108-15.
16. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10:122-63.
17. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218-26.
18. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831-6.
19. Elbasha E, Dasbach E, Insinga R. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13:28-41.
20. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and costeffectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96:604-15.